Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Sio Gene Therapies Inc. | a093020exhibit3211.htm |
| EX-31.2 - EX-31.2 - Sio Gene Therapies Inc. | a093020exhibit3121.htm |
| EX-31.1 - EX-31.1 - Sio Gene Therapies Inc. | a093020exhibit3111.htm |
| EX-4.1 - EX-4.1 - Sio Gene Therapies Inc. | exhibit41-formofstockcer.htm |
| 10-Q - 10-Q - Sio Gene Therapies Inc. | siox-20200930.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Sio Gene Therapies Inc. (the “Company”) for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, David Nassif, Chief Financial Officer and Chief Accounting Officer, General Counsel of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: November 13, 2020 | By: | /s/ David Nassif | ||||||
| David Nassif | ||||||||
| Chief Financial Officer and Chief Accounting Officer, General Counsel | ||||||||
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the SEC or its staff upon request.